Get Social
Facebook-f
Youtube
949.642.1361
Home
Our Team
Lisa N. Abaid
Tiffany L. Beck
John V. Brown
Alberto A. Mendivil
Office Staff
Locations
Irvine Gynecologic Oncologists
Newport Beach Gynecologic Oncologists
Orange Gynecologic Oncologists
Hoag Infusion Center, Newport Beach
Hoag Infusion Center, Irvine
News
Gynecologic Oncology
Portal
Patient Info
Helpful Information about the Novel Coronavirus (COVID-19)
Videos
Testimonials
Contact Us
Reviews
Menu
Home
Our Team
Lisa N. Abaid
Tiffany L. Beck
John V. Brown
Alberto A. Mendivil
Office Staff
Locations
Irvine Gynecologic Oncologists
Newport Beach Gynecologic Oncologists
Orange Gynecologic Oncologists
Hoag Infusion Center, Newport Beach
Hoag Infusion Center, Irvine
News
Gynecologic Oncology
Portal
Patient Info
Helpful Information about the Novel Coronavirus (COVID-19)
Videos
Testimonials
Contact Us
Reviews
Sign up now to hear Dr. Abaid speak October 29, 6pm
Patient-Focused Webinar On Paclitaxel/Carboplatin
The Foundation for Women's Cancer (FWC) hosted a webinar on Oct. 24 titled, You Got This: Getting Prepared for Paclitaxel/Carboplatin Chemotherapy. This patient-focused webinar covered how these chemotherapy drugs work; what to expect on the first day of treatment and their progress; tips and strategies to help prepare for chemotherapy treatment; and the onset and duration of side effects, and when to call their doctor. Speakers included Judith A. Smith, PharmD, BCOP, CPHQ, FCCP, FISOPP; Rebecca A. Brooks, MD and Kim Hurley—an ovarian cancer survivor whose paclitaxel/carboplatin chemotherapy treatment lasted for seven months. Click here to watch.
FDA grants priority review to olaparib for maintenance therapy of BRCA-positive ovarian cancer
The FDA granted priority review to a supplemental new drug application that seeks approval of olaparib tablets for maintenance therapy of women with newly diagnosed BRCA-mutated advanced ovarian cancer. The designation applies to use of the agent for women who are in complete or partial response after first-line standard platinum-based chemotherapy. The FDA is expected to make a decision on the application in the first quarter of 2019. Click here to read more.
Helpful Information about the Novel Coronavirus (COVID-19)
Read More »
A Comprehensive Approach to Gynecologic Cancer Care
Read More »
Dr. Lisa Abaid is Named Co-Director of High-Risk Breast & Ovarian Cancer Program
Read More »
HPV vaccination and regular Pap screenings can greatly reduce risk of cervical cancer
Read More »
Dr. Abaid discusses Genetic Screening
Read More »
Congrats Dr. Lisa Abaid on the 10,000th Robotic Surgery
Read More »
Copyright © 2022
Optimized360 LLC
| All Rights Reserved |
Privacy Policy
|
Terms of Use
|
Disclaimer
|
Web Accessibility Statement
Skip to content
Open toolbar
Accessibility Tools
Increase Text
Decrease Text
Grayscale
High Contrast
Negative Contrast
Light Background
Links Underline
Readable Font
Reset
Automated page speed optimizations for fast site performance